BioSpace News Archive

The first cancer patient was successfully dosed in the phase I/IIa clinical study Tumorad-01 with the drug candidate in the radionuclide therapy program Tumorad, 177Lu-SN201.

Perimed AB, a leading medical device company in the vascular segment, is thrilled to announce a significant milestone in its growth journey.

Innovent Biologics, Inc. announces that the New Drug Application for mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, for chronic weight management in adults with obesity or overweight.

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented “Investigating the effects of AXL inhibition during respiratory viral infections” during the 6th Forum on Respiratory Infections in Glasgow, Scotland.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open.

Entrada Therapeutics, Inc. today announced it will participate in the following two investor conferences: Oppenheimer 34th Annual Healthcare Life Sciences Conference.

IRLAB Therapeutics announced that the company’s year-end report for the period January-December 2022, has been published.

Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.

Scion Life Sciences announced the final close of its inaugural fund, which was oversubscribed with $310 million in capital commitments.

Insulet Corporation announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes.